About
Ben is a senior associate in our intellectual property group.
Ben advises clients on IP, technology and commercial mattes, with a particular focus on the life sciences sector.
Ben's practice involves negotiating complex licensing and collaboration arrangements and other strategic alliances and advising on IP issues arising in the context of M&A, joint venture and IPOs. Ben also advises on business separation and commercial issues in the context of complex IP/tech-heavy carve-outs.
Ben's contentious experience includes the litigation and arbitration of patents, trade marks and trade secrets and IP licence disputes.
Additional Information
- Novartis on the separation and spin-off of Sandoz, its generics and biosimilars division.
- Ontario Teachers’ Pension Plan Board on its joint investment with Nordic Capital in Advanz Pharma.
- Hasten Biopharmaceuticals on its acquisition of the product portfolios in South East Asia from Celltrion Healthcare.
- Recordati, a portfolio company of CVC Capital Partners, on its acquisition of EUSA Pharma (UK) Limited.
- Universal Music Group on the IP aspects of its majority Investment in Mavin Global.
- EdF on the IP aspects of its acquisition of part of GE Steam Power’s nuclear power business.
- General Atlantic's BeyondNetZero on the acquisition of a minority stake in ABB E-mobility.
- AstraZeneca on its cancer drug patent licence dispute with Tesaro.
- Advising global telecoms company on a major, multi-jurisdictional SEP/FRAND dispute, including advising on client’s SEP portfolio vetting project.
Ben Cohen
Senior Associate
T +44 20 7936 4000
london Office
100 Bishopsgate
EC2P 2SR london